Trial · NCT05697770
SODium BICarbonate for Metabolic Acidosis in the ICU
NCT05697770, Phase 3, Active not recruiting, Australian and New Zealand Intensive Care Research Centre
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. SODium BICarbonate for Metabolic Acidosis in the ICU. Trials, record NCT05697770. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05697770
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- SODium BICarbonate for Metabolic Acidosis in the ICU
- NCT number
- NCT05697770
- Status
- Active not recruiting
- Phases
- Phase 3
- Enrollment
- 500 participants, actual
- Lead sponsor
- Australian and New Zealand Intensive Care Research Centre
- Conditions
- Metabolic Acidosis, Shock
- Interventions
- Sodium bicarbonate, 5% Dextrose
- First posted
- 2023-01-26
- Last updated
- 2026-03-27
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | MAKE30 score | 30 days or at hospital discharge (whichever occurs first) | The primary outcome is MAKE30 from the date of randomisation. MAKE30 is defined as a composite of death from any cause, receipt of RRT, or persistent renal dysfunction (defined as an elevation of the creatinine level to ≥200% of baseline), all censored at hospital discharge or 30 days, whichever occurs first. |
| Secondary | 30-day in-hospital mortality | 30 days or at hospital discharge (whichever occurs first) | All-cause in-hospital mortality at day 30 |
| Secondary | Receipt of renal replacement therapy in the first 30 days | 30 days or at hospital discharge (whichever occurs first) | Receipt of renal replacement therapy in the first 30 days |
| Secondary | Persistent renal dysfunction | 30 days or at hospital discharge (whichever occurs first) | Defined as an elevation of the creatinine level to ≥ 200% of baseline |
| Secondary | Renal replacement therapy dependence at day 30 | 30 days or at hospital discharge (whichever occurs first) | Defined by the receipt of any form of renal replacement therapy within ± 10 days of the 30-day time point following randomisation |
| Secondary | ICU mortality | 30 days or at hospital discharge (whichever occurs first) | All-cause ICU mortality at day 30 |
| Secondary | Hospital mortality | 90 days or at hospital discharge (whichever occurs first) | All-cause hospital mortality at day 90 |
| Secondary | 90-day in-hospital mortality | 90 days or at hospital discharge (whichever occurs first) | All-cause mortality at day 90 |
| Other | Recurrence of metabolic acidosis in the first 7 days after randomization | 7 days after randomization | Defined as pH \< 7.30, BE ≤ -4 mEq/L and PaCO2 ≤ 45 mmHg |
| Other | Incidence and the maximum stage of AKI in the first 7 days after randomization | 7 days after randomization | According to KDIGO criteria |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05697770
GET https://conductscience.org/api/trials/v1/NCT05697770/registered